The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What plasma short-chain fatty acids are predictors of response to GvHD therapy?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Shernan G. Holtan, University of Minnesota, Minneapolis, US. We asked, What plasma short-chain fatty acids are predictors of response to graft-versus-host disease therapy?

What plasma short-chain fatty acids are predictors of response to GvHD therapy?

Holtan describes the results of a clinical trial evaluating how acute GvHD treatment response relates to plasma levels of short-chain fatty acids. In general, levels of butyrate are higher in patients responding to therapy.

Share: